MedPath

Probiotics-Supplemented Feeding in Extremely Low Birth Weight Infants

Phase 2
Completed
Conditions
Low Birth Weight
Interventions
Dietary Supplement: Probiotic supplementation (Lactobacillus rhamnosus GG and Bifidobacterium infantis)
Other: Placebo
Registration Number
NCT01164124
Lead Sponsor
Vermont Oxford Network
Brief Summary

The overall purpose of this research is to test whether adding a supplement to the feeding of extremely low birth weight infant (infants weighing less than 2 pound 2 oz at birth) will help him/her achieve full feeding faster and achieve better weight gain.

Detailed Description

The overall purpose of this research is to test whether adding a supplement to the feeding of extremely low birth weight infant (infants weighing less than 2 pound 2 oz at birth) will help him/her achieve full feeding faster and achieve better weight gain. The study also will evaluate the benefit of that feeding supplement in decreasing the rate of infection (in the blood or in the urine) and antibiotics use in those infants.

When babies are born, the digestive system (the gastrointestinal tract) is sterile. There are no bacteria residing in their gut. When babies start feeding, it is normal for the intestine to start growing several types of bacteria. These normal (good) bacteria are thought to be helpful in keeping the intestine healthy. This is not the case in premature infants. It takes premature infants a longer time to grow bacteria in their intestines and they have fewer numbers of bacteria. In addition, the bacteria premature infants grow are not the normal one that we see in healthy infants. Instead they grow unhealthy (bad) bacteria that can potentially play a role in causing infection in the blood and urine.

Adding the normal (good) bacteria to the breast milk or infant formula might help to protect premature babies from developing blood or urine infection. In addition, adding the good bacteria might be beneficial in terms of better tolerance to milk feeding. As a result, babies may have less episodes of feeding holding and have better weight gain. Two species of bacteria, called Lactobacillus and Bifidobacteria, have been used to study this in other studies of premature babies. These two species are the most plentiful bacteria seen in the bowels of full term babies.

Participation in the study involves enrolling premature babies to receive supplement to the feeding when he/she ready to feed. Babies will be randomly assigned to receive either a bacteria (probiotic) supplement or be fed without supplement. The supplement will be added to one feeding each day. Enrolled babies will continue to get the supplement for 6-10 week. Other than the feeding supplement, being in this study will not affect care.

The main outcomes of the study will be feeding tolerance and growth. Other complications associated with prematurity, on particular infection of either the gastrointestinal tract or the blood stream will be evaluated.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
101
Inclusion Criteria
  • birth weight less than or equal to 1000 grams,
  • appropriately grown for gestational age,
  • age 1 to 14 days inclusive,
  • intention to start enteral feeds,
  • written informed consent obtained
Exclusion Criteria
  • known life-threatening congenital anomaly or condition affecting
  • gastrointestinal function,
  • previous NEC or gastrointestinal perforation,
  • previous supplementation with probiotics
  • previous enteral feedings

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Probiotic supplementationProbiotic supplementation (Lactobacillus rhamnosus GG and Bifidobacterium infantis)500 million CFU of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brand Inc.) and 500 million CFU of Bifidobacterium infantis (Align, Procter \& Gamble.Inc)
Routine feedingsPlacebo-
Primary Outcome Measures
NameTimeMethod
Growth28 days from study entry

Average weight gain and growth velocity during the first 28 days from initiation of feeding.

Feeding Tolerance28 days from study entry

Volume of feeding per day during the first 28 days from the initiation of feeding.

Secondary Outcome Measures
NameTimeMethod
Complications of prematurityuntil hospital discharge

common complications of prematurity including but not limited to sepsis, necrotizing enterocolitis, and mortality.

Antimicrobial therapy34 weeks post menstrual age

Days of antimicrobial treatment until 34 weeks post menstrual age.

Trial Locations

Locations (3)

Cardinal Glennon Children's Hospital

🇺🇸

Saint Louis, Missouri, United States

St. John Hospital & Medical Center

🇺🇸

Detroit, Michigan, United States

VT Children's at Fletcher-Allen Health Care

🇺🇸

Burlington, Vermont, United States

© Copyright 2025. All Rights Reserved by MedPath